Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/5/2010

and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; our ability to comply with the terms of our loan agreement, and draw down additional amounts under our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the impact of healthcare reform legislation; our ability to timely complete a required post-marketing efficacy study of OFIRMEV in infants and neonates; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence® and OFIRMEV™ are trademarks of Cadence Pharmaceuticals, Inc.Contact:

William R. LaRue

Nicole FoderaroSVP & Chief Financial Officer

Media & Investor RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone:
415-946-1058 – office415-215-5643 – cellCADENCE PHARMACEUTICALS, INC.(a development stage company)CONDENSED STATEMENTS OF OPERATIONS(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2010 2009 2010 2009 Operating expenses:Research and development

$
3,537,167$
4,464,587$
,564,603$
4,683,908Sales and marketing

4,129,0083,068,63214,857,9584,790,886General and administrative

2,937,2693,762,8519,526,6339,549,203Other

483,469(
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
7. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
10. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
11. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a ... its President and Chief Executive Officer, David Hansen ... Investor Conference being held at the Luxe Sunset ... on June 1-3, 2015. Mr. Hansen will ... progress made in the last year and plans for ...
(Date:5/28/2015)... 28, 2015  IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has submitted its ... Food and Drug Administration (FDA) of 2015, which brings ... at the FDA to twenty-five. Jason ... "Our team continues to execute on the targets we ...
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "2015 Strategies in ...  report to their offering.      ... to the UK NAT laboratory practice, as ... and technological trends with significant market impact ...
Breaking Medicine Technology:MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 2MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 4IGI Laboratories, Inc. Announces Third ANDA Submission Of 2015 2
... Reportlinker.com announces that a new market research report ... Drug Delivery in Central Nervous System Diseases - ... The delivery of drugs ... in the treatment of neurological disorders. Drugs may ...
... Robbins & Myers, Inc. (NYSE: ... its Romaco businesses to a group of funds led ... investment firm.  Total consideration was approximately euro 65 million ... and euro 4 million of assumed liabilities and is ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
(Date:5/28/2015)... 2015 Career Step, an online provider ... announce that Career Step Executive Vice President Mike Hodgson ... webinar presented by ICD10monitor in conjunction with Kimberly J. ... Hodgson and Ms. Carr will be discussing the importance ... transition. , “We have worked closely with HRS on ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Sunshine ... Treatment and Drug Rehabilitation programs at http://www.sunshinecoasthealthcentre.ca ... in its information outreach to the Toronto, Ontario, ... in Toronto, and has enhanced its online location ... is our primary treatment center, we realize that ...
(Date:5/28/2015)... May 28, 2015 Peggy J. Lynam, PT, ... to the American Physical Therapy Association House of Delegates for ... at their Delegate Assembly. This will be her second ... serves as coordinator and principle spokesperson for the Chapter delegation ... of Directors or Delegate Assembly may direct the Chief Delegate ...
(Date:5/28/2015)... 28, 2015 The 110-mile April 24-26 ... ride from national non-profit World T.E.A.M. Sports is featured ... Talking With Heroes . , Host Bob Calvert and ... veteran and civilian riders, sponsors and staff members. The ... includes a musical performance by The American Bombshells and ...
(Date:5/27/2015)... (PRWEB) May 28, 2015 Cincinnati Veterans ... informational Open House May 30 from noon-2p.m. in the ... about how caregivers can offer full-time assistance to Veterans ... through a comprehensive survey process conducted by the medical ... residence as a medical foster home, the caregiver must ...
Breaking Medicine News(10 mins):Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 2Health News:Toronto Alcohol Treatment and Drug Rehab Local Information Page Updated, Announces Sunshine Coast Health Center 3Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 3
... is available in German . Lung tumors ... one cancer in three is lung cancer. Each year, there are ... a tumor can be detected, the greater the chance of healing ... the tumor-related complaints resemble chronic inflammatory reactions. To get a more ...
... be active in killing cells also promotes cellular survival through ... is actually necessary for survival of septic injury, Future research ... developing new treatments for sepsis PROVIDENCE, R.I. ... plays a dual role in the liver during sepsis. The ...
... poverty have health problems as adults. But a new study ... social cohesiveness and control get some measure of protection; they,re ... The new study, published in Psychological Science , a ... a long-term examination of children growing up poor in rural ...
... these late effects of treatment, the health care services can, ... the treatment, and, on the other hand, find appropriate ways ... in adolescence and adulthood. The cancer care services in ... affected by cancer as early as 1987. Twenty years later, ...
... Amanda Gardner HealthDay Reporter , TUESDAY, Feb. ... many Americans have out-of-control blood pressure and cholesterol levels ... health officials warn. According to the latest report ... one-third of U.S. adults have hypertension (high blood pressure), ...
... gifts to medical science is stirring excitement with the ... inhabiting cyanobacterium appears to be an ideal blueprint ... other bone diseases. That,s the conclusion of a study ... Medicinal Chemistry Letters . By some estimates, more ...
Cached Medicine News:Health News:Early detection of lung cancer 2Health News:The 'death switch' in sepsis also promotes survival 2Health News:Having a strong community protects adolescents from risky health behaviors 2Health News:PanCareSurFup: Major EU project to tackle complications of childhood cancer treatment 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 2Health News:Half of Adults Have Hypertension or High Cholesterol: CDC 3
Diamond Reusable Probed work with all ACMI™ instrument inserts. Dual trumpet valves provide smooth, effective fingertip control over suction and irrigation....
... Clinicians are demanding smaller, higher ... their clinical and operational challenges. The ... a powerful architecture for superb High ... mobility and ease-of-use; and a versatile ...
The new PERIMOUNT Magna heart valve (bioprosthesis), with its true supra-annular design, offers optimal hemodynamics and flow characteristics for treatment of aortic heart valve disease....
... the world wide sole distributor of CONOR ... conventional drug eluting stents, the CONOR Medsystems ... stent designed to provide advanced drug delivery ... profiles to be tailored to optimize the ...
Medicine Products: